DAlcohol use disorder
Not recommended
Alcohol use disorder
Not recommended
In Russia, Biotredin (L-threonine + pyridoxine) is registered in the state drug register (GRLS) for relief of alcohol withdrawal and reduction of alcohol craving as part of combination therapy. PubMed holds no clinical trials of this combination for that use; the supporting data are limited to a few uncontrolled, non-indexed observations. The guideline on medicines for alcohol dependence and the Socidrogalcohol clinical guideline do not list threonine with pyridoxine among treatments with demonstrated efficacy, where the recognised options are naltrexone, acamprosate, nalmefene and disulfiram. A critical review of off-label and investigational drugs for alcohol use disorder (Fischler et al., 2022) likewise does not mention it. No harm has been documented at the registered doses, so the rating is D: benefit is unproven and current data show no net negative.
Sources
ICD-10: F10.2 · ICD-11: 6C40.2